Current Epidemiology data on HCV/HBV in Europe

Homie Razavi

First European Roundtable on Hepatitis Cure & Eradication

September 9, 2015
Disclosure:

H. Razavi is the Managing Director of CDA and has received no personal remuneration.

The HCV portion of this work was supported by Gilead Sciences.
The HBV portion of this work was supported by the John C. Martin Foundation.
Agenda

- Hepatitis C
- Hepatitis B
In 2014, there were 3.7 million RNA+ (viremic) HCV infections in the Europe Union (EU) – 8.5M RNA+ and 13.3M anti-HCV+ in all Europe.

In EU, G1 (69%) dominates followed by G3 (17%) and G2 (9%).

<table>
<thead>
<tr>
<th>Country</th>
<th>Prevalence (Viremic)</th>
<th>Total Infected (Viremic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>0.0%-0.6%</td>
<td>0-200K</td>
</tr>
<tr>
<td>Belgium</td>
<td>0.6%-0.8%</td>
<td>200K-650K</td>
</tr>
<tr>
<td>Croatia</td>
<td>0.8%-1.3%</td>
<td>650K-1.9M</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>1.3%-2.9%</td>
<td>1.9M-3.5M</td>
</tr>
<tr>
<td>Denmark</td>
<td>2.9%-7.8%</td>
<td></td>
</tr>
</tbody>
</table>

Italy, Romania, Spain, Germany, Poland, France, UK, Greece and Portugal account for 85% of total infections in EU

There were 3.7 million viremic HCV Infection in 2014

HCV (viremic) prevalence ranges from 0.1-3% in the region
The fibrosis distribution in each country correlates strongly with the median age of the HCV infected population.
Approximately, 80,000 HCV patients are treated in EU annually.
Despite the availability of DAAs, the increase in treatment has been modest in European countries.
Increased screening and treatment is required to make a significant impact on HCV prevalence in EU.

Bubble size corresponds to HCV Prevalence Rate.
Agenda

- Hepatitis C
- Hepatitis B
In 2014, an estimated 4.1 million HBsAg+ individuals were in EU

Analysis based on literature search. Data has not been validated with individual countries.
Romania, Poland, France, UK, Spain, Italy, Greece and Germany account for 85% of all HBV infections in EU

There were 41 million HBsAg+ individuals in 2014

The prevalence of HBsAg ranged from 0.2-4.4% in EU
The Percentage of one year olds receiving 3 doses of HepB immunization has increased to 90% in EU

Source: WHO - Global Health Observatory Data Repository
Elimination of HBV among infants is a feasible goal for any country

- Cuba achieved zero new HBV infections among infants in 2014
  - Screen all pregnant women
  - Use locally produced Hepatitis B immune globulin (HBIG) and treatment in the last trimester
  - Start immunization of infants at births and treat with HBIG if HBsAg positive
In Conclusion:

- Relative to other regions, the total number of HCV and HBV infections is low.
- Unfortunately, treatment remains low in the region (below what is required to achieve elimination).
- Elimination of HBV (zero new cases) is feasible in EU but national strategies are required.
- A significant reduction in HBV related HCC and decompensated cirrhosis among adults is also feasible in EU through treatment.
More to Follow in the next few months:

- Detailed HCV Epidemiology data by country & region
- Interactive HCV strategy web-based model
- HBV epidemiology data by country & region
- HCC cases attributed to HBV and HCV
- Liver transplants attributed to HBV and HCV
- Web-based model for HBV eradication among infants
- Web-based model for HBV treatment among adults